Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial
1. Eli Lilly's pill, orforglipron, outperformed Novo Nordisk in diabetes management. 2. Orforglipron showed better weight loss and blood sugar control over 52 weeks. 3. Eli Lilly plans to apply for FDA approval in 2026 and global launch by 2025. 4. Concerns remain regarding comparison with higher doses of Novo Nordisk's drugs. 5. Gastrointestinal side effects were noted, with higher discontinuation rates in the trial.